Neurotech International appoints Dr Alexandra Andrews as Chief Executive Officer

SYDNEY, AUSTRALIA: Neurotech International Limited (ASX: NTI) announced the appointment of Dr Alexandra Andrews as Chief Executive Officer, effective from 8th March 2022.

Dr Andrews holds a Doctor of Philosophy (PhD) in Neuroscience from the University of Western Australia.

Neurotech International appoints Dr Alexandra Andrews as Chief Executive Officer
Dr Alexandra Andrews

She brings expertise in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.

Previously, she was Director of Operations at NeuroScientific Biopharmaceuticals Ltd. Throughout her career, Dr Andrews has worked closely with clinical researchers, investors and entrepreneurs, providing scientific and strategic input into clinical development plans and overseeing manufacturing.

Dr Alexandra Andrews brings commercial, transactional and project management experience, including via her earlier role at Linear Clinical Research where she focused on attracting partnerships with US biotechnology and pharmaceutical companies, and managing trial logistics.

“I am very pleased to have an executive and a scientist of Dr Andrews’ stature join Neurotech. She comes on board at a pivotal point – just ahead of the results release from our Phase I/II clinical studies in children with Autism Spectrum Disorder,” said Brian Leedman, Chairman of Neurotech International.

“Alex has worked with me previously and her appointment will further strengthen management’s scientific and commercial leadership experience as the Company progresses with the development of unique cannabis strains for the treatment of neurological disorders”.

Dr Alexandra Andrews said, “I am delighted to be joining Neurotech International as CEO at this exciting time as clinical research into Neurotech’s low level THC cannabis plant strains is unfolding – initially in children with Autism, then in other neurological and inflammatory disorders. I am passionate about improving patient outcomes and am looking forward to collaborating with the team in leveraging NTI’s novel technology to accelerate advancements in health and medicine.”

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains.

www.neurotechinternational.com

About the author

Leave a Reply

Your email address will not be published.